Accelerate biotechnology

Correction Science Times publication Nov 17th on Emergency Use Listing nOPV2

In an article with the title “New Polio Vaccine Becomes The First Vaccine Under the WHO’s Emergency Use Listing”, The Science Times stated that that Batavia Biosciences developed the nOPV2 vaccine that has now been approved for emergency use by the WHO. This statement is, in fact, incorrect, the nOPV2 vaccine approved for emergency use was developed and manufactured by BioFarma, Indonesia.

Batavia Biosciences was not involved in any way in the preparation or review of the article and has not been contacted by the author or organization prior to publishing. Moreover, the quote from Batavia’s CEO, Menzo Havenga, set out in the article was taken from a previously published press release and Batavia Biosciences did not give permission for this quote to be used in this context.

We have repeatedly contacted The Science Times to request a correction and they have not replied to our requests.

COVID-19 Message

Please read the message from our executive management regarding the precautionary measures at Batavia Biosciences.